Physician profile
Jona Gorra
NPI 1619900461
$1,946.54
in general payments reported to CMS, 2019-2025
19 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $117 · 2021: $177 · 2022: $402 · 2023: $345 · 2024: $525 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.46 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $424.46 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.06 | 2019-2024 | Jardiance |
| Abbvie INC. | $181.27 | 2021-2024 | |
| Lilly USA, LLC | $180.53 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $159.46 | 2020-2024 | Repatha |
| Pfizer INC. | $112.14 | 2019-2025 | |
| Dexcom, INC. | $87.11 | 2022-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $78.54 | 2022-2024 | Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $67.88 | 2021-2023 | |
| Abbott Laboratories | $67.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.97 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $52.67 | 2019 | |
| Medtronic, INC. | $31.18 | 2021 | |
| Smith+Nephew, INC. | $24.21 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.20 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $20.68 | 2022 | |
| Scilex Pharmaceuticals INC. | $18.88 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.44 | 2020 | |
| Merck Sharp & Dohme LLC | $15.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jona Gorra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.